TAS-114 is a dual inhibitor of dUTPase/dihydropyrimidine dehydrogenase (DPD), and can improving the therapeutic efficacy of fluoropyrimidine.

the cytotoxicity of 5-Fluorouracil (5-FU) increased by TAS-114 (1-10 μM; 72 hours) and 5-FU,2′-deoxy-5-fluorouridine (FdUrd) against various cancer cell lines in dose-dependent manner.

In mice, the antitumor activity of 5-FU when co-administers with Capecitabine (539 mg/kg/day) increased by TAS-114 (37.5-1,200 mg/kg/day; orally; 1-14 days) .

1198221-21-4

C21H29N3O6S

451.54

TAS-114

DMSO:100 mg/mL (221.46 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years